siRNA targeting stathmin inhibits invasion and enhances chemotherapy sensitivity of stem cells derived from glioma cell lines

Acta Biochim Biophys Sin (Shanghai). 2014 Dec;46(12):1034-40. doi: 10.1093/abbs/gmu099. Epub 2014 Oct 27.

Abstract

Glioma is one of the most highly angiogenic tumors, and glioma stem cells (GSCs) are responsible for resistance to chemotherapy and radiotherapy, as well as recurrence after operation. Stathmin is substantial for mitosis and plays an important role in proliferation and migration of glioma-derived endothelial cells. However, the relationship between stathmin and GSCs is incompletely understood. Here we isolated GSCs from glioma cell lines U87MG and U251, and then used siRNA targeting stathmin for silencing. We showed that silencing of stathmin suppressed the proliferation, increased the apoptosis rate, and arrested the cell cycle at G2/M phase in GSCs. Silencing of stathmin in GSCs also resulted in inhibited the migration/invasion as well as the capability of vasculogenic mimicry. The susceptibility of GSCs to temozolomide was also enhanced by stathmin silencing. Our findings suggest stathmin as a potential target in GSCs for glioma treatment.

Keywords: glioma stem cells; invasion; stathmin; temozolomide.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use*
  • Base Sequence
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / pathology
  • Cell Line, Tumor
  • DNA Primers
  • Gene Silencing
  • Glioma / drug therapy*
  • Glioma / pathology
  • Humans
  • Neoplastic Stem Cells / drug effects*
  • RNA Interference
  • RNA, Small Interfering / genetics*
  • Real-Time Polymerase Chain Reaction
  • Stathmin / genetics
  • Stathmin / physiology*

Substances

  • Antineoplastic Agents
  • DNA Primers
  • RNA, Small Interfering
  • Stathmin